DE69933755T2 - Ef-tu mrna als marker für lebensfähige bakterien - Google Patents
Ef-tu mrna als marker für lebensfähige bakterien Download PDFInfo
- Publication number
- DE69933755T2 DE69933755T2 DE69933755T DE69933755T DE69933755T2 DE 69933755 T2 DE69933755 T2 DE 69933755T2 DE 69933755 T DE69933755 T DE 69933755T DE 69933755 T DE69933755 T DE 69933755T DE 69933755 T2 DE69933755 T2 DE 69933755T2
- Authority
- DE
- Germany
- Prior art keywords
- sequence
- oligonucleotide
- seq
- mrna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 14
- 239000003550 marker Substances 0.000 title claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 71
- 230000003321 amplification Effects 0.000 claims abstract description 70
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 58
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 claims abstract description 52
- 239000000523 sample Substances 0.000 claims abstract description 41
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 38
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 34
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 29
- 241000186362 Mycobacterium leprae Species 0.000 claims abstract description 23
- 230000035899 viability Effects 0.000 claims abstract description 19
- 230000001580 bacterial effect Effects 0.000 claims abstract description 16
- 241000894007 species Species 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 43
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 238000001514 detection method Methods 0.000 claims description 30
- 241000588724 Escherichia coli Species 0.000 claims description 25
- 238000013518 transcription Methods 0.000 claims description 22
- 230000035897 transcription Effects 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 3
- 230000002787 reinforcement Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000064099 Massilioclostridium coli Species 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 5
- 206010036790 Productive cough Diseases 0.000 abstract description 4
- 210000003802 sputum Anatomy 0.000 abstract description 4
- 208000024794 sputum Diseases 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 210000001124 body fluid Anatomy 0.000 abstract description 2
- 239000010839 body fluid Substances 0.000 abstract description 2
- 230000014670 detection of bacterium Effects 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- BZSVVCFHMVMYCR-UHFFFAOYSA-N 2-pyridin-2-ylpyridine;ruthenium Chemical compound [Ru].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1 BZSVVCFHMVMYCR-UHFFFAOYSA-N 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150099542 tuf gene Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241001301450 Crocidium multicaule Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 241000289661 Dasypus novemcinctus Species 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 241000181697 Mycobacterium tuberculosis str. Erdman = ATCC 35801 Species 0.000 description 1
- 241000202952 Mycoplasma fermentans Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 101150101373 fus gene Proteins 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98200184 | 1998-01-23 | ||
| EP98200184 | 1998-01-23 | ||
| PCT/EP1999/000323 WO1999037804A2 (en) | 1998-01-23 | 1999-01-19 | EF-Tu mRNA AS A MARKER FOR VIABILITY OF BACTERIA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69933755D1 DE69933755D1 (de) | 2006-12-07 |
| DE69933755T2 true DE69933755T2 (de) | 2007-09-13 |
Family
ID=8233311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69933755T Expired - Lifetime DE69933755T2 (de) | 1998-01-23 | 1999-01-19 | Ef-tu mrna als marker für lebensfähige bakterien |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6489110B1 (enExample) |
| EP (1) | EP1049809B1 (enExample) |
| JP (2) | JP4634604B2 (enExample) |
| AT (1) | ATE343642T1 (enExample) |
| AU (1) | AU2717699A (enExample) |
| CA (1) | CA2318726C (enExample) |
| DE (1) | DE69933755T2 (enExample) |
| ES (1) | ES2275336T3 (enExample) |
| WO (1) | WO1999037804A2 (enExample) |
| ZA (1) | ZA99362B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2388461C (en) * | 1999-09-28 | 2013-06-11 | Infectio Diagnostic (I.D.I.) Inc. | Highly conserved genes and their use to generate probes and primers for the detection of microorganisms |
| EP1950313A3 (en) * | 2000-03-27 | 2010-12-08 | GlaxoSmithKline LLC | Detection of viable agents |
| JPWO2002052034A1 (ja) * | 2000-12-26 | 2004-04-30 | 大島 譲二 | 生死判別方法及び核酸増幅方法 |
| CN1298739C (zh) * | 2001-04-30 | 2007-02-07 | 诺沃罗吉斯有限公司 | 抗菌剂 |
| EP1529117A2 (en) * | 2002-08-08 | 2005-05-11 | University of Lausanne | Method for the rapid assessment of the presence and viability of bacterial cells and use thereof |
| GB0324650D0 (en) * | 2003-10-22 | 2003-11-26 | Acolyte Biomedica Ltd | Using nucleic acids for clinical microbiology testing |
| US7309589B2 (en) * | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
| AU2006274507B2 (en) * | 2005-07-27 | 2013-08-29 | Diagnostic Array Systems Pty Ltd | Method for the detection and/or identification of a microorganism |
| EP1924700A4 (en) * | 2005-07-27 | 2010-09-01 | Diagnostic Array Systems Pty L | METHOD FOR DETECTION AND / OR IDENTIFICATION OF A MICROORGANISM |
| JP5593037B2 (ja) * | 2009-03-12 | 2014-09-17 | 東洋水産株式会社 | 細菌測定用プライマーおよび細菌測定方法 |
| US11441167B2 (en) | 2019-11-20 | 2022-09-13 | Roche Molecular Systems, Inc. | Compositions and methods for rapid identification and phenotypic antimicrobial susceptibility testing of bacteria and fungi |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71715A0 (en) * | 1983-08-05 | 1984-09-30 | Miles Lab | Method,gene probes and test kit for detecting bacteria by nucleic acid hybridization |
| US5130238A (en) * | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| JPH09504182A (ja) | 1994-08-18 | 1997-04-28 | アクゾ・ノベル・エヌ・ベー | Ｃｍｖ核酸の増幅用及び検出用プライマー及びプローブ |
| US5994066A (en) | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| JPH09248186A (ja) * | 1996-03-15 | 1997-09-22 | Oozeki Kk | ラクトバチルス属微生物のポリペプチド鎖延長因子遺伝子Ｔｕおよびその利用 |
| US6444444B1 (en) | 1996-07-10 | 2002-09-03 | Aventis Pasteur Limited | Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof |
| FR2755145B1 (fr) * | 1996-10-28 | 1999-01-15 | Gervais Danone Co | Procede de mise en evidence de contaminants microbiologiques vivants dans un echantillon de produit a usage alimentaire |
-
1999
- 1999-01-19 AT AT99907386T patent/ATE343642T1/de not_active IP Right Cessation
- 1999-01-19 WO PCT/EP1999/000323 patent/WO1999037804A2/en not_active Ceased
- 1999-01-19 ZA ZA9900362A patent/ZA99362B/xx unknown
- 1999-01-19 US US09/600,770 patent/US6489110B1/en not_active Expired - Lifetime
- 1999-01-19 ES ES99907386T patent/ES2275336T3/es not_active Expired - Lifetime
- 1999-01-19 CA CA002318726A patent/CA2318726C/en not_active Expired - Lifetime
- 1999-01-19 DE DE69933755T patent/DE69933755T2/de not_active Expired - Lifetime
- 1999-01-19 AU AU27176/99A patent/AU2717699A/en not_active Abandoned
- 1999-01-19 EP EP99907386A patent/EP1049809B1/en not_active Expired - Lifetime
- 1999-01-19 JP JP2000528711A patent/JP4634604B2/ja not_active Expired - Lifetime
-
2010
- 2010-10-06 JP JP2010226408A patent/JP2011050387A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2717699A (en) | 1999-08-09 |
| ZA99362B (en) | 1999-07-19 |
| US6489110B1 (en) | 2002-12-03 |
| JP2011050387A (ja) | 2011-03-17 |
| CA2318726C (en) | 2009-07-28 |
| ATE343642T1 (de) | 2006-11-15 |
| JP2002500893A (ja) | 2002-01-15 |
| CA2318726A1 (en) | 1999-07-29 |
| WO1999037804A2 (en) | 1999-07-29 |
| ES2275336T3 (es) | 2007-06-01 |
| EP1049809B1 (en) | 2006-10-25 |
| DE69933755D1 (de) | 2006-12-07 |
| EP1049809A2 (en) | 2000-11-08 |
| JP4634604B2 (ja) | 2011-02-16 |
| WO1999037804A3 (en) | 1999-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60217837T2 (de) | Nachweis von methicillin-resistenten staphylococcus aureus bakterien (mrsa) | |
| DE3486467T2 (de) | Verfahren zum Nachweis, Identifizieren und Quantifizieren von Organismen und Viren | |
| DE3856455T2 (de) | Selektive Amplifikation von Oligonukleotidenzielsequenzen | |
| DE69429626T2 (de) | Oligonukleotide und Verfahren zum Nachweis von Chlamydia trachomatis | |
| DE3752172T2 (de) | Nukleinsäuresonden zum Nachweis und/oder zur Quantifizierung von nicht-viralen Organismen | |
| DE69833160T2 (de) | Amplifizierung und Detektion von HIV-1 und/oder HIV-2 | |
| DE69534516T2 (de) | Gleichzeitiger nachweis, identifizierung und differenzierung von eubakterien unter verwendung eines hybridisierungs-assays | |
| DE68921287T2 (de) | Nukleotidesequenzen, die ein Protein mit Ureareaktivität kodieren. | |
| DE69524083T2 (de) | Stoffen und verfahren zum nachweis von mycobakterium tuberculosis | |
| DE69308381T2 (de) | Sonden für Mycobakterien | |
| DE69019795T2 (de) | Verfahren zur Feststellung der Empfindlichkeit von HIV-1 für Zidovudine und dazu geeignete Oligonukleotide. | |
| DE69425450T2 (de) | Detektion und Identifikation von Mycobakterien | |
| JP2011050387A (ja) | バクテリアの生存率に関するマーカーとしてのＥＦ−ＴｕｍＲＮＡ | |
| DE69514883T2 (de) | Spezies-spezifischer Nachweis von Mycobacterium Kansasii | |
| DE69627625T2 (de) | Die amplifizierung und bestimmung von arten des mycobakterium avium-komplexes | |
| DE69423131T2 (de) | Verfahren zur Behandlung von Mycobakterien enthaltenden Auswürfen | |
| EP0739988B1 (de) | Verfahren zur Gattungs- und speziesspezifische Identifizierung von Legionellen | |
| US5916744A (en) | Testing for infestation of rapeseed and other cruciferae by the fungus Leptosphaeria maculans (blackleg infestation) | |
| EP1389242B1 (de) | Nachweis und differenzierung von mikroorganismen der spezies yersinia pestis/yersinia pseudotuberculosis | |
| DE69121975T2 (de) | Spezifischer Nachweis von Mycobacterium Tuberculosis | |
| DE69732926T2 (de) | Primer und sonden zur amplifizierung, erkennung und typisierung von mycoplasma pneumoniae | |
| DE60122067T2 (de) | Vervielfältigung und Detektion von Legionella pneumophila Nukleinsäuren | |
| DE69711073T2 (de) | Verfahren zur erkennung von lebenden mikrobiologischen verunreinigungen in einer lebensmittelprobe | |
| DE69735046T2 (de) | Zusammensetzungen und Verfahren für den Nachweis von Mycobacterium kansasii | |
| DE60129896T2 (de) | Amplifizierung und Detektion von Mycoplasma pneumoniae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |